The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Design, execute, and interpret quantitative biophysical experiments to characterize protein quality, molecular interactions, binding mechanisms, kinetics, thermodynamics, stability, oligomerization, and higher-order complex formation, integrating these data to drive project decisions.